Peptide Comparison
CartalaxvsBPC-157
Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Cartalax
2–5 mg
BPC-157
250–500 mcg
Frequency
Cartalax
Once daily
BPC-157
Once daily
Administration
Cartalax
Oral (capsule)
BPC-157
Subcutaneous injection
Cycle Length
Cartalax
12+ weeks
BPC-157
4-6 weeks
Onset Speed
Cartalax
Gradual (3-4 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Cartalax
Moderate human trials (Phase 1-2)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Anti-Aging
Healing & Recovery
Hormone Support
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Cartalax
Molecular Formula
C12H19N3O8
Molecular Weight
333.3 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids
Bioavailability
Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)
CAS Number
Not yet registered (research compound)
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Cartalax
BPC-157
Applications
Best
suited for
Cartalax
Cartilage regeneration and protection in age-related osteoarthritis
Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Connective tissue repair and maintenance in aging individuals
Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Cartalax
Common
- Mild injection site reaction
- Mild GI discomfort
- Mild fatigue
- Transient joint stiffness
Uncommon
- Temporary increase in joint discomfort
Serious
- No documented serious adverse effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Cartalax
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive joint infection — treat infection before initiating peptide bioregulator therapy
- xMalignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Cartalax if...
- Cartilage regeneration and protection in age-related osteoarthritis
- Connective tissue repair and maintenance in aging individuals
- Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
- Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health